Veloxis Pharmaceuticals has agreed to pay more than $46 million to resolve criminal and civil allegations that it used kickbacks to drive prescriptions and purchases of Envarsus XR, its kidney-transplant drug. According to the Department of Justice, the resolution includes a deferred prosecution agreement tied to a criminal information filed in the U.S. District Court for the District of Massachusetts, underscoring the government’s continued focus on pharmaceutical marketing practices that allegedly influence prescribing decisions.

The matter is significant because it combines both criminal and civil exposure in a single healthcare-fraud resolution.